Edition:
United States

Oncosil Medical Ltd (OSL.AX)

OSL.AX on Australia Stock Exchange

0.11AUD
22 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.11
Open
$0.12
Day's High
$0.12
Day's Low
$0.11
Volume
37,257
Avg. Vol
693,016
52-wk High
$0.18
52-wk Low
$0.08

Latest Key Developments (Source: Significant Developments)

Oncosil Medical says co has been granted UK Central Ethics Approval
Monday, 3 Apr 2017 09:35pm EDT 

Oncosil Medical Ltd : Asx alert-UK central ethics approval-OSL.AX .Has been granted UK central ethics approval for its global clinical study programme for pancreatic cancer.  Full Article

Oncosil Medical says co has been granted UK Central Ethics Approval
Monday, 3 Apr 2017 07:42pm EDT 

Oncosil Medical Ltd : Asx alert-UK central ethics approval-OSL.AX .Has been granted UK central ethics approval for its global clinical study programme for pancreatic cancer.  Full Article

Oncosil Medical receives MHRA approval to commence study in UK
Sunday, 12 Feb 2017 05:58pm EST 

Oncosil Medical Ltd - : MHRA approval to commence study in uk-osl.ax .Medicines and health care products regulatory agency has approved commencement of Pancreatic Cancer clinical study in UK.  Full Article

Oncosil Medical receives FDA approval for investigational device exemption
Monday, 1 Aug 2016 09:57pm EDT 

Oncosil Medical Ltd : FDA IDE approval . Says has received investigational device exemption (IDE) approval from the U.S. food and drug administration (FDA) . Will now initiate clinical investigation for Oncosil for treatment of eligible subjects with pancreatic cancer .  Full Article

Oncosil Medical updates on CE Mark submission
Monday, 29 Feb 2016 03:31pm EST 

Oncosil Medical:Also actively pursuing its investigation device exemption with the United States food and drug administration.Continues to be in active engagement with the notified body for the CE Mark submission.Says IDE submission process is proceeding and a face-to-face meeting with the FDA will be sought.  Full Article

Oncosil Medical secures A$10 million institutional placement
Tuesday, 2 Feb 2016 08:22pm EST 

Oncosil Medical:A$10 million institutional placement.Placement is by way of subscription agreement for approximately 45.5 million new ordinary shares in Oncosil Medical at $A0.22 per share.Currently has an investigational device exemption (ide) filing in progress with the US food and drug administration (FDA).  Full Article

Oncosil Medical Ltd appoints Tom Milicevic as CFO
Wednesday, 21 Oct 2015 07:39pm EDT 

Oncosil Medical Ltd:Oncosil Medical appoints new CFO Tom Milicevic.Milicevic will replace Oncosil medical's current joint company secretaries, Peter Casey and Nicholas Falzon.  Full Article

OncoSil Medical Limited provide the update on its Conformité Européenne (CE) Mark application
Sunday, 11 Oct 2015 06:09pm EDT 

OncoSil Medical Limited:Says the following update on its Conformité Européenne (CE) Mark application for the Company's OncoSilTM localised radiation treatment for cancer.OncoSil Medical now advises that the Fast Track Face-to-Face review phase has been completed, and it now awaits the final outcome of the review as the Notified Body continues its assessment over the coming weeks.Company was pleased with the review meeting and anticipates that the Notified Body will make a decision in respect of the CE Mark for OncoSilTM in November.  Full Article

More From Around the Web

BRIEF-Oncosil Medical receives institutional review board approval from Md Anderson Cancer Center

* Oncosil receives institutional review board approval from md anderson cancer center for pancreatic clinical study programme Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)